News ArchivesRead News

New discovery offers hope for Parkinson's

Saturday May 11, 2013

Times of India - Scientists have discovered the three-dimensional structure of the protein Parkin, a finding which may provide new ways to develop drugs to slow the progression of Parkinson's disease.

Researchers from McGill University worked in collaboration with teams led by Dr Edward A Fon at the Montreal Neurological Institute and Hospital - The Neuro, and Dr Kalle Gehring in the Department of Biochemistry at the Faculty of Medicine.

Mutations in Parkin cause a rare hereditary form of Parkinson's disease and are likely to also be involved in more commonly occurring forms of Parkinson's disease.

The Parkin protein protects neurons from cell death due to an accumulation of defective mitochondria. Mitochondria are the batteries in cells, providing the power for cell functions.

This new knowledge of Parkin's structure has allowed the scientists to design mutations in Parkin that make it better at recognising damaged mitochondria and therefore possibly provide better protection for nerve cells.

"The majority of Parkinson's patients suffer from a sporadic form of the disease that occurs from a complex interplay of genetic and environmental factors which are still not fully understood," said Fon, neurologist at The Neuro and head of the McGill Parkinson Programme.

"A minority of patients have genetic mutations in genes such as Parkin that cause the disease. Although there are differences between the genetic and sporadic forms, there is good reason to believe that understanding one will inform us about the other.

"It's known that toxins that poison mitochondria can lead to Parkinson's-like symptoms in humans and animals. Recently, Parkin was shown to be a key player in the cell's system for identifying and removing damaged mitochondria," Fon said.

Gehring likens Parkin to a watchdog for damaged mitochondria.

"Our structural studies show that Parkin is normally kept in check by a part of the protein that acts as a leash to restrict Parkin activity. When we made mutations in this specific 'leash' region in the protein, we found that Parkin recognised damaged mitochondria more quickly," Gehring said.

"If we can reproduce this response with a drug rather than mutations, we might be able to slow the progression of disease in Parkinson's patients," Gehring added.

The research will be published in the journal Science.

Recent News

Sep 27 - The beginning of the end? The race for a Parkinson’s cure
Sep 22 - Understanding Parkinson's Disease: An Interview with Jon Palfreman
Sep 22 - Living with Lewy Body Dementia
Sep 21 - Adults with autism likely to develop Parkinson’s disease, says study
Sep 16 - Everyday activity more beneficial than occasional strenuous exercise for Parkinson’s disease
Sep 14 - UNC scientists create smarter immune cells to treat Parkinson's disease
Sep 9 - A newly discovered brain disease may point to something disturbing about Alzheimer’s and Parkinson’s
Sep 7 - Treatment for Parkinson's could replace surgery
Sep 4 - Asthma May Influence Risk of Parkinson's Disease
Sep 4 - Researchers Explore Memory Problems Related to Parkinson's
Sep 3 - Press Release: ACADIA Pharmaceuticals Submits New Drug Application for NUPLAZID™ for the Treatment of Parkinson’s Disease Psychosis
Aug 28 - Brain cells 'burn out' in Parkinson's disease
Aug 24 - Study Details Process Involved in Parkinson’s Disease
Aug 24 - Google Reveals Gigantic Ambitions To Fight Cancer, Diabetes, Parkinson's, Heart Problems
Aug 20 - Two proteins work together to help cells eliminate trash; Parkinson's may result
Aug 17 - Scientists visualize critical part of basal ganglia pathways
Aug 17 - VA benefits office seeks all vets exposed to Agent Orange
Aug 12 - New, rapid dementia screening tool rivals 'gold standard' clinical evaluations
Aug 11 - Strolling in Seaside, fighting Parkinson's
Aug 11 - Scientists probing molecular origins of Parkinson's disease highlight two proteins